<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422978</url>
  </required_header>
  <id_info>
    <org_study_id>H17-02157</org_study_id>
    <nct_id>NCT03422978</nct_id>
  </id_info>
  <brief_title>The Effects of Dexmedetomidine on Intravenous Anesthetic Requirements for Children Undergoing Dental Procedures</brief_title>
  <acronym>Dexmed-PRS</acronym>
  <official_title>Anesthetic Sparing Effect of Dexmedetomidine During TIVA With Propofol and Remifentanil for Children Undergoing Dental Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to determine the propofol and remifentanil sparing effects of a&#xD;
      single dose of dexmedetomidine in the dental population. The investigators plan to do this by&#xD;
      performing a blinded study with 4 test groups (3 experimental and 1 control), using BIS&#xD;
      monitoring to titrate TIVA infusion to an acceptable depth of anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:&#xD;
&#xD;
      To determine an optimal dose of dexmedetomidine for its anesthetic sparing effect, without&#xD;
      extending post-operative stay.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The investigators hypothesize that dexmedetomidine will cause a clinically significant&#xD;
      reduction of 30% in the amount of propofol and remifentanil required to maintain adequate&#xD;
      depth of anesthesia, as monitored through the Bispectral Index.&#xD;
&#xD;
      Justification:&#xD;
&#xD;
      The dose-sparing effect of dexmedetomidine on TIVA requirements and the dose-response&#xD;
      relationship between dexmedetomidine and TIVA dosing regimens has not been explored in young&#xD;
      children. This study will have many relevant applications to many areas of pediatric&#xD;
      anesthesia practice, such as craniofacial and neurosurgery, sedation techniques in diagnostic&#xD;
      and interventional radiology, out of OR sedation, and in all young children in whom&#xD;
      minimizing anesthesia exposure is increasingly sought given possible concerns over the long&#xD;
      term neurocognitive effects of surgery and anesthesia in early life.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To investigate the dose-sparing effect on a propofol/remifentanil infusion of bolus doses of&#xD;
      dexmedetomidine and to characterize the dose-response relationship between dexmedetomidine&#xD;
      doses and TIVA dose reduction.&#xD;
&#xD;
      Research Design:&#xD;
&#xD;
      The investigators propose a randomized, 4-group comparative study to characterize the effects&#xD;
      of different bolus doses of dexmedetomidine on the infusion requirements of propofol and&#xD;
      remifentanil. The study-specific interventions will include a bolus of dexmedetomidine (or&#xD;
      placebo) at induction of anesthesia, and maintenance of anesthesia, titrated to a Bispectral&#xD;
      index of 50-60, with propofol and remifentanil infusions.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      Standard statistical analysis will be undertaken using R Foundation for Statistical&#xD;
      Computing, Vienna, Austria). Summary data will be tabulated and presented as median (IQR).&#xD;
      Mean infusion rates of propofol and remifentanil will be compared between groups using&#xD;
      Wilcoxon signed-rank test, with 95% confidence intervals obtained by the Hodges-Lehmann&#xD;
      estimator. Dose (in mcg/kg) of additional opioids given in PACU will be tabulated and&#xD;
      compared using Fisher's exact test. Bonferroni corrections will be applied as appropriate&#xD;
      whenever multiple comparisons are performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Assessor of sedation scores post-procedure will be blinded to group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol and remifentanil sparing</measure>
    <time_frame>Through length of procedure, an average of 1.5 hours</time_frame>
    <description>Propofol and remifentanil sparing as measured by time-averaged, total administered doses of propofol (mg/kg) and remifentanil (mcg/kg) compared to the placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Propofol and remifentanil infusion rate reduction</measure>
    <time_frame>Through length of procedure, an average of 1.5 hours</time_frame>
    <description>Change in infusion rates of propofol and remifentanil (in micrograms/kg/min), measured over time compared to the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PACU sedation</measure>
    <time_frame>30min post-procedure</time_frame>
    <description>Sedation will be scored from 0 (alert) to 4 (unarousable) using the University of Michigan sedation score (UMSS) at 10, 20, and 30 minutes post discontinuation of the infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU pain scores</measure>
    <time_frame>30min post-procedure</time_frame>
    <description>Pain will be scored from 0 (no pain) to 10 (severe pain), using the FLACC pain scale for ages 2-7 and the FACES pain scale for ages 8-10, and total fentanyl doses in mcg/kg given in the Post Anesthetic Care Unit will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Anesthetic Sparing</condition>
  <arm_group>
    <arm_group_label>Saline bolus</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10mL normal saline solution administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.50 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1.00 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Single dose dexmedetomidine administered over 60 seconds post-induction.</description>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.50 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 1.00 mcg/kg</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Single dose normal saline administered over 60 seconds post-induction.</description>
    <arm_group_label>Saline bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA 1-2&#xD;
&#xD;
          -  Elective dental surgery&#xD;
&#xD;
          -  Planned general anesthesia with TIVA&#xD;
&#xD;
          -  Age 2-10 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General anesthesia with inhalation induction&#xD;
&#xD;
          -  Documented seizure disorder&#xD;
&#xD;
          -  Cardiac disease&#xD;
&#xD;
          -  Cardiac rhythm abnormalities&#xD;
&#xD;
          -  Chronic hypertension&#xD;
&#xD;
          -  Weight &lt; 5th centile or &gt; 95th centile for age&#xD;
&#xD;
          -  Pre-operative administration of anxiolytics (such as benzodiazepines or opioid&#xD;
             analgesics)&#xD;
&#xD;
          -  Hypersensitivity to dexmedetomidine or any other study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Whyte, MBBS, FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Children's Hospital, Department of Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Poznikoff, BSc</last_name>
    <phone>604-875-2000</phone>
    <phone_ext>1989</phone_ext>
    <email>andrew.poznikoff@cw.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Whyte, MBBS, FRCA</last_name>
    <phone>604-875-2711</phone>
    <email>swhyte@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Children's Hospital - Department of Anesthesia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Poznikoff, BSc</last_name>
      <phone>604-875-2000</phone>
      <phone_ext>1989</phone_ext>
      <email>andrew.poznikoff@cw.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Simon Whyte, MBBS, FRCA</last_name>
      <phone>604-875-2711</phone>
      <email>swhyte@cw.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Whyte, FRCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randa Ridgway, FRCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Gorges, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Poznikoff, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://part.bcchr.ca/</url>
    <description>Pediatric Anesthesia Research Team website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Simon Whyte</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

